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a b s t r a c t
Nanothickness encapsulation using a layer-by-layer technique has applications in several
areas of diabetes research, including improved glucose sensors, islet cell transplantation and
oral insulin delivery. We have fabricated microvesicles containing a fluorescence lifetime-
based glucose sensing system, with bacterial glucose-binding protein as the glucose receptor.
Such sensors are suitable for impregnation in the dermis as a ‘smart tattoo’ type of non-
invasive glucose monitoring technology. Nanoencapsulation of islet cells is intended to
alleviate the immediate blood-mediated inflammatory reaction which is responsible for early
islet loss post-transplant. In an allogeneic diabetic mouse model, nanoencapsulated islets
with phosporylcholine-modified polysaccharide coating, significantly extended survival of
transplanted islets. In early studies aimed at formulating an effective oral insulin preparation,
insulin-chitosan colloids coated with nanolayers of chitosan and heparin had enhanced acid
stability and effectively lowered blood glucose in an animal model.
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1. Introduction
Nanomedicine involves the manufacture, measurement and
clinical application of very small (nano)-scale structures
(usually 1–100 nm in size), – membranes and films, particles,
vesicles, probes and sensors being typical examples [1,2]. Such
structures usually have altered properties, such as increased
strength, or changed activity or porosity, compared to larger-
scale constructions. This article reviews one of the most active
and promising research areas in nanomedicine: the use of
multilayered nano-thickness films for encapsulating cells,
sensors and drug delivery systems. The special characteristics
of these films include rapid transit of some substances but
isolation of others, control of biocompatibility and the local
in vivo environment, and robust containment. Applications of
this technology are being seen in at least three major areas of
diabetes: in vivo glucose sensing, cell therapeutics (particu-
larly islet cell transplantation) and insulin delivery (potentially
for oral administration).
2. Layer-by-layer technology
The layer-by-layer (LBL) technique for formation of nano-
membranes involves the alternate deposition of polymer
electrolytes of positive or negative charge on a template [3,4].
Examples of some of the polymers used are polyamino acids
(e.g. poly[L-glutamic acid] and poly[L-lysine]), polysaccharides
(e.g. heparin, alginate and chitosan) and synthetic polymers
(e.g. poly[allylamine hydrochloride] and poly[styrene sul-
phate]). Originally developed as a coating technology for flat
surfaces, LBL technology has been now extensively used for
encapsulation of particles, proteins and cells. The amount
deposited in each layer is self limited, and independent of time
and concentration. The mild nature of the coating procedure
and the ability to tune permeability and biocompatibility by
the number of layers, the composition of the polymers and the
coating conditions, and the ability to incorporate additional
bioactive molecules in the layers, have made LBL technologies
particularly suitable for encapsulation and in vivo adminis-
tration of biological moieties such as proteins and cells.
3. Nanoencapsulation for improved glucose
sensors
3.1. Fluorescence-based sensors and ‘smart tattoos’
Non-invasive glucose sensing has long been a dream
of patients with diabetes and researchers, and many
technologies have been investigated, including near-infrared
(NIR), Raman, photoacoustic and impedance spectroscopy,
optical coherence tomography, polarimetry and reverse
iontophoresis [5]. None has yet seen application in clinical
practice, largely because of interferences and imprecision and
alternative technologies are therefore being explored. In
recent years, fluorescence has emerged as a promising
technology for both minimally invasive, re-implantable
glucose sensors and non-invasive glucose sensing [6]. Fluo-
rescence is very sensitive and not subject to electroactive
interferents in the tissues, and since the tissues are transpar-
ent to several centimetres of NIR light, when the fluorophore is
excited and emits in the NIR range, intradermally or
subcutaneously impregnated fluorescence-based sensors
can be potentially used as a non-invasive technology [2], with
measurement from the skin surface. This so called ‘smart
tattoo’ concept [2] was probably first suggested by Russell et al.
[7], though in the context of hydrogel glucose-sensing micro-
spheres, rather than encapsulated sensors. Recent work on
hydrogel fibres incorporating a fluorescent glucose sensing
system with excitation at 350–420 nm and emission at 460–
520 nm, implanted into the dermis of the mouse ear and with
skin-surface fluorescence recording [8], suggests that at least
under some circumstances (perhaps if the sensor is close to
the skin surface) the fluorophore need always not be operative
in the NIR range.
Florescence changes can be measured as either intensity or
the lifetime of the decay [6,9]. Since the latter is essentially
independent of light scattering, fluorophore concentration
and photobleaching, it is particularly useful for in vivo sensors
such as a smart tattoo. Thus, although implanted fluorescence
probes may become coated in vivo by protein or encapsulated
by cells which would decrease fluorescence intensity, the
lifetime will remain relatively constant.
3.2. Nanoencapsulated glucose sensors
Microvesicles created by LBL encapsulation and containing
fluorescence-based glucose sensors have been described by
our own group [2,10], as well as McShane et al. [11–15]. In
general, hollow-vesicle sensors can be formed by LBL deposi-
tion around a removable template such as calcium carbonate
which can then dissolved (e.g. using ethylenediaminetetraa-
cetic acid, EDTA) [15–17]. One way of introducing the sensing
element into the vesicles is by uptake into preformed vesicles
(loading by diffusion), with alteration of the membrane pore
size by changing factors such as pH or ionic strength, so as to
either increase uptake during loading or trap the sensing
material after uptake [15]. A method of higher efficiency is first
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to adsorb or absorb the sensing element to a sacrificial
template (or to co-precipitate the template and sensing
reagent), form LBL nanomembranes around the template/
sensor and then dissolve the template [10,16,17] (Fig. 1).
Several fluorescence-based glucose sensing assays have
been incorporated into multilayer nanocapsules, operating as
either competitive or non-competitive systems. In competitive
systems, there is a change in fluorescence resonance energy
transfer (FRET) when glucose binds to a fluorescent-labelled
receptor such as tetramethyl rhodamine isothiocyanate
labelled concanavalin A (FRET acceptor), in competition with
a fluorescent glucose analogue such as fluorescein isothiocy-
anate-labelled dextran (FRET donor) [12]. Other competitive
systems use apo glucose oxidase (glucose oxidase with the
prosthetic group removed) as the glucose receptor, labelled
with a variety of acceptors, together with dextran labelled with
one of several donors [13,14]. Entrapped glucose oxidase may
also be used as a sensor with detection of oxygen consumption
via a co-entrapped oxygen-sensitive dye Ru(dpp) [18].
3.3. LBL nanoencapsulated glucose sensor based on
glucose-binding protein
Most of our recent sensing research has been centred on
fluorescently-labelled bacterial glucose/galactose-binding
protein (GBP) as the glucose receptor, configured in a non-
competitive assay system. When glucose binds to GBP, the
tertiary structure of the protein changes markedly, with the
two lobes of the molecule closing round glucose and the
binding site [19]. We covalently linked the environmentally-
sensitive fluorophore, badan (the fluorescence of which
increases in a non-polar environment), to a cysteine mutation
near the binding site of GBP, so that the consequent decrease
in polarity at the binding site is marked by an increase in
fluorescence intensity and mean lifetime [10,20].
When measuring fluorescence lifetime by time-correlated
single-photon counting, the fluorescence decay can be
resolved into two components: a short-lifetime component
of 0.8 ns, equivalent to the open form of GBP with no glucose
bound and badan in a polar environment, and a long-lifetime
component of 3.1 ns equivalent to the closed form of GBP with
bound glucose and badan in a hydrophobic environment [10].
When glucose is added to GBP–badan, the fraction of the long-
lifetime component increases and the fraction of the short
lifetime component decreases [10].
Native GBP has a binding constant (Kd) in the micromolar
range and therefore is unsuitable for use as a clinical sensor, so
we engineered a series of mutants of GBP with the intention of
increasing the Kd. We found that the triple mutant H152C/
A213R/L238S has a Kd of 11 mmol/l and an operating range
from 1–100 mmol/l glucose, and is therefore suitable for use in
a clinical sensor [21].
We constructed microvesicles encapsulating the GBP–
badan and suitable for smart tattoo, by first absorbing GBP–
badan onto a template of calcium carbonate, then forming the
shell around the template using the LBL technique (alternating
poly[L-lysine] with poly[L-glutamic acid] or heparin), followed
by dissolution of the template with EDTA (Fig. 1). The changes
in the fluorescence lifetime on addition of glucose can be
visualised by fluorescence lifetime imaging microscopy [10]
(Fig. 1).
The challenges for the future with a smart tattoo include
maintaining survival of the microsensors in vivo, showing lack
of toxicity of the materials and efficient fluorescence recording
Fig. 1 – Upper: encapsulation of glucose-binding protein (GBP) labelled with the fluorophore, badan, in nanoencapasulated
vesicles. GBP-badan is absorbed to calcium carbonate microparticles, then multiple polymer nanolayers are deposited,
followed by dissolution of the template with EDTA. Lower: addition of glucose to nanoencapsulated glucose-sensing
vesicles increases the fluorescence lifetime, and can be visualised by fluorescence lifetime imaging microscopy (blue = low
fraction and red = high fraction of long-lifetime, closed form of GBP). (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of the article.)
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 0 ( 2 0 1 3 ) 1 6 2 – 1 6 9164
from the skin surface. Though, as mentioned above, there is
some evidence that fluorophores that are excited and emit in
the same spectral region as badan can be interrogated from
the skin surface when impregnated into the dermis [8], better
functioning may be achieved by substituting badan for an
environmentally sensitive fluorophore operative in the NIR
region.
4. Nanoencapsulation of transplanted
pancreatic islets
4.1. The advantages of LBL encapsulation
In addition to an insufficient supply of donor islets and
immune rejection unless toxic immunosuppressant drugs are
used, islet transplantation as a viable routine therapy for type
1 diabetes is currently also limited by early loss of functional
islets after the clinically preferred intrahepatic transplanta-
tion, attributed to a deleterious response by the host innate
immune system, and known as an immediate blood-mediated
inflammatory reaction (IBMIR) [22,23]. Clinical and animal
studies have revealed that infiltration of leukocytes and an
inflammatory response, together with activation of the
complement and coagulation cascades leads to up to two
thirds loss of islets within the first few days post transplanta-
tion [23]. Islet encapsulation is usually considered mainly as a
technology to protect the islets from immune rejection whilst
allowing glucose, oxygen and nutrient entry into and insulin
release from the capsule-contained islets [24]. However, a
biocompatible encapsulation technology that is focused as
well, or instead, on restricting or preventing IBMIR and early
islet destruction by host innate immune attack may be a major
contribution to improving the clinical efficacy of islet
transplantation.
Pancreatic islet encapsulation has traditionally included
the use of microcapsules of, for example, alginate, which are
produced via various droplet-generating processes [24].
Problems of conventional microencapsulation include hypox-
ic death of the cells and subsequent graft failure due to poor
diffusion of oxygen and nutrients into the central cell mass, as
well as incomplete immune protection and inadequate
biocompatibility of the encapsulating materials, leading to
non-specific protein adsorption and fibroblast overgrowth. In
addition, microcapsules have large and therefore unsuitable
transplant volumes for the intraportal transplantation route.
An attractive alternative strategy is to nano-engineer
around individual islets a conformal nanocoating (nanoen-
capsulation) via deposition of nanofilms [25]. Conformal
coating of isolated cells or cell clusters offers a mechanism
for generating a selectively permeable and isolating layer close
to the cell surface. The coating is very thin (nanometers),
greatly reducing diffusional distances for O2 and nutrients,
thus potentially improving cell survival and function. More
importantly for islet encapsulation and delivery is the fact that
conformal coating does not substantially increase the encap-
sulated islet volume and is therefore compatible with
intraportal transplantation. Several methods of conformal
coating have been developed recently, including surface
‘PEGylation’ (attachment of poly[ethylene glycol]) and
multilayer encapsulation, but some of these approaches
suffer from poor biocompatibility of the synthetic encapsu-
lating material, or incomplete surface coverage, neither of
which is acceptable for islet encapsulation for clinical use.
LBL deposition, as noted above, generates a multilayered,
thin film from oppositely charged species, deposited in
succession on a solid support, which in this context is a cell
or group of cells. A particular benefit of LBL technologies for
cell encapsulation is that the layered structures can be
fabricated with nanoscale precision (i.e. reproducibility),
tuneable permeability and modifiable surface characteristics.
Early studies with LBL encapsulation of islets employed
cations such as poly(allylamine hydrocholoride) and anions
such as poly(sytyrene sulphonate) [26], but encapsulation with
passive barrier materials alone is generally insufficient to
protect donor tissue from early loss or eventual rejection.
However, multilayer films offer a versatile and facile platform
for incorporating diverse biologically active agents into
conformal coatings. Functional biomolecules of suitable
charge like anticoagulants, complement regulatory proteins
or anti-inflammatory agents can be incorporated into the
linear polyelectrolyte multilayers during assembly, making
the surface properties bioactive. Several studies have demon-
strated that localised delivery of therapeutics to the site of
grafts by conformal coatings may block coagulation, comple-
ment cascade and other islet destruction pathways, thereby
significantly improving graft survival and reducing the islet
mass necessary for reversing hyperglycaemia.
4.2. Modification of coating materials
4.2.1. Phosphorylcholine-modified polysaccharide coatings
We have developed an islet-coating protocol using alternate
layers of phosphorylcholine (PC)-derived polysaccharides
(chitosan or chondroitin-4-sulphate) and alginate as coating
materials [27,28] (Fig. 2). We introduced the protein-repelling
zwitterionic PC modification in the coating constructs to
minimise interactions between islets and the environment.
The PC moiety, which is a component of plasma cell
membranes, confers hydrophilicity, haemocompatibility and
resistance to non-specific protein absorption, thus potentially
inhibiting the development of fibrosis, supporting endothelial
cell growth and also carrying anticoagulatory properties, all of
which are likely to enhance islet survival in vivo and
encourage host integration.
Whereas naked, unencapsulated islets were rejected after
7–10 days when transplanted below the kidney capsule in an
allogeneic diabetic mouse model, nanoencapsulated islets
survived for at least 28–37 days in most animals, at which time
nephrectomy was performed to examine islet histology.
Moreover, nanoencapsulated islets maintained glycaemic
control in the diabetic animals after an intraperitoneal glucose
tolerance test [28].
4.2.2. PEGylation
PEGylation increases the biocompatibility of biomaterials by
increasing hydrophilicity and preventing direct adsorption of
proteins, as well as concealing surface structures, thereby
preventing activation of the complement and coagulation
cascade systems.
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Teramura and Iwata [29] have developed a method for
surface modification of pancreatic islets with PEG-lipid for
improvement of graft survival after intraportal transplanta-
tion. Cell damage of PEG-islets after transplantation was
suppressed, and the graft survival was significantly prolonged,
compared with bare islets transplanted into livers of diabetic
mice.
Conformal, nanothin PEG coatings have also been reported
by the group of Chaikof et al. [30–32] where islets were
encapsulated using LBL deposition of poly(L-lysine)-g-PEG-
(biotin) and streptavidin (with poly [L-lysine]/alginate seed
coating), and poly(L-lysine)-g-PEG copolymers and alginate
(via polyion complex formation). Grafting of PEG chains to
poly(L-lysine) was found to reduce the cytotoxicity of the
polycations.
4.3. Modification of coating to incorporate therapeutic
molecules
4.3.1. Anti-Fas antibodies for preventing autoreactivation of T
cells
Surface-conjugation of apoptosis-inducing anti-Fas monoclo-
nal antibodies to the surfaces of PEG-modified hydrogels
embedding islets has been employed to provide a surface that
actively attempts to locally down-regulate the autoimmune
response by destroying autoreactive T cells against the grafted
pancreatic islet cells [33].
4.3.2. Thrombomodulin for regulating coagulation and
inflammation
Exposure of islets to fresh blood activates thrombotic reactions
which are involved in the destruction of transplanted islets.
Chemoselective conjugation of antithrombotic azido-function-
alized thrombomodulin to pancreatic islets was achieved by
ligation to a surface-bound bifunctional PEG linker [34].
Thrombomodulin was also immobilized on islet surfaces
through streptavidin–biotin interactions. The presence of the
tethered thrombomodulin resulted in a significant increase in
the production of activated protein C, with a reduction in islet-
mediated thrombogenicity. The thrombomodulin-reengi-
neered surface reduced donor cell-mediated procoagulant
and proinflammatory responses [35].
4.3.3. Heparin coating for inhibiting IBMIR
All currently identified systemic inhibitors of the IBMIR are
associated with a significantly increased risk of bleeding or
other side effects. To avoid systemic treatment, a continuous
heparin coating to the islet surface has been investigated as
way of rendering the islet graft more blood biocompatible. A
biotin/avidin technique was used to conjugate preformed
heparin complexes to the surface of pancreatic islets [36]. This
endothelial-like coating was achieved by conjugating 40 IU
heparin per clinical islet transplant. Both in an in vitro model
and in an allogeneic porcine model of clinical islet transplan-
tation, this heparin coating provided protection against IBMIR.
Heparinized islets cultured for 24 h had unaffected insulin
release after glucose challenge, and heparin-coated islets
normalised glycaemia in diabetic mice in a manner similar to
untreated islets.
4.3.4. Urokinase for inhibiting IBMIR
PEG-lipid and PEG-urokinase have been immobilized onto
islets through hydrophobic interaction and streptavidin/biotin
interaction or DNA hybridization [37–42]. Efficacy of surface
modification for the inhibition of IBMIR was proven using a
syngenic mouse transplantation model. Outcomes evaluated
were blood insulin levels immediately after transplantation,
blood glucose levels, and histochemical analyses of trans-
planted islets within the liver.
4.3.5. Heparin/sCR1 for inhibiting IBMIR
Human soluble complement receptor 1 (sCR1) and heparin
have been co-immobilized onto the surfaces of islet cells in a
LBL manner [42,43]. sCR1 molecules carrying thiol groups were
immobilized through maleimide-PEG-phospholipids an-
chored in the lipid bilayers of islet cells. Heparin was
Fig. 2 – Nanoencapsulation of pancreatic islets by layer-by-layer deposition of ultra-thin polyelectrolyte nanofilms. Islets
were coated with a cocktail of chitosan-phosphorylcholine (PC), alginate and chondroitin-4-sulphate-PC. Adapted from ref.
[28].
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immobilized on the sCR1 layer via the affinity between sCR1
and heparin, and additional layers of sCR1 and heparin were
formed in a similar way layer-by-layer.
4.3.6. Extracellular matix peptide
Extracellular matrix IKVAV peptide has been immobilized on
the surface of pancreatic islets through strain-promoted
azide–alkyne cycloaddition with cell surface azides [44]. The
cyclooctyne-derivatized IKVAV peptide conjugate enabled
efficient modification of the pancreatic islet surface in less
than 60 min. The ability to bind peptides at controlled surface
densities was demonstrated in a quantitative manner using
microarrays.
5. Nanoencapsulation of insulin for controlled
release
5.1. Oral insulin
Various delivery strategies for overcoming the formidable
barriers of enzymatic digestion and poor absorption of orally
delivered insulin have been explored, including using carrier
systems in which insulin is entrapped into particulate
structures such as microspheres or nanospheres [45]. These
insulin-loaded nano/microparticles can have limited colloidal
stability and readily dissociate and dissolve in the acidic
gastric conditions. Although the therapeutic effect is fast and
intense after oral administration of, for example, insulin–
chitosan nanoparticles, the oral bioavailability of the drug
from an immediate release dosage form is poor and highly
variable. Designing a dissolution barrier allowing control over
the release of insulin from the microparticles by multilayer
encapsulation could help overcome these problems.
5.1.1. Chitosan/heparin multilayer-coated insulin particles
We have been researching a novel application for LBL
technology to nanoencapsulate insulin-incorporated micro-
colloids with very high content of the bioactive protein (90% by
wt) and controllable drug release rate (Song, Zhi, Pickup,
unpublished observations). Insulin–chitosan micro-colloids
were surface-coated by multilayered shells comprising chit-
osan and heparin. By adding PEG in the aqueous assembly
solutions, the insulin loss can be dramatically reduced during
deposition steps and stable micro-colloidal capsules are
achievable. Deposition of chitosan–heparin ultrathin films
onto the insulin particles via polyion complex formation was
found to enhance the particle colloidal stability at acidic pH
conditions and control loading/release characteristics, there-
by achieving more efficient delivery of oral insulin (Fig. 3).
Such chitosan–heparin multilayer encapsulated insulin–chit-
osan complexes significantly lowered blood glucose levels in
diabetic mice, while the insulin capsules alone caused no
reduction.
5.1.2. Chitosan/albumin multilayers
Chitosan and albumin layers have been used to stabilize
insulin nanoparticles formed along with calcium alginate,
dextran sulphate and a poloxamer (a triblock copolymer) [46].
Insulin nanoencapsulation reduced plasma glucose levels to
40% of the basal values with a sustained hypoglycaemic effect
over 24 h. Pharmacodynamic and pharmacokinetic param-
eters were evaluated at a dose of 50 IU/kg nanoencapsulated
insulin, and 13% oral bioavailability was obtained.
Fig. 3 – Light and fluorescent images of nanoencapsulated insulin–chitosan (A) and insulin (B) particles at pH 2.0. Left:
brightfield; right: fluorescence. At pH 2.0, the insulin alone capsules are empty, caused by the insulin particle dissolution.
For encapsulated insulin–chitosan particles, the particles remained intact.
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5.1.3. Fe3+/dextran/protamine multilayers
Insulin-loaded microcapsules have also been prepared via
LBL complex formation of oppositely charged Fe3+ and
dextran sulphate (DS) onto the surface of insulin micro-
particles [47]. Fe3+ was combined with DS via both
electrostatic interaction and chemical complexation, lead-
ing to the formation of a stable complex of Fe3+/DS.
Protamine was used as the outermost layer of the
microcapsules to facilitate nuclear delivery. The micro-
capsules successfully entrapped insulin with efficiency of
70% and drug loading content of 46%. The insulin-loaded
microcapsules significantly improved glucose tolerance for
up to 12 h (insulin-loaded microcapsules with 10 bilayers).
Moreover, the microcapsules with protamine as the
outermost layer displayed a prolonged and stable glu-
cose-lowering profile in vivo over a period of over 6 h,
compared with Fe3+ as the outermost layer.
6. Conclusions
A significant body of research now shows that multilayer
nanoencapsulation has promise in developing improved
glucose sensors and enhancing islet survival after transplant.
This work now needs to be extended to clinical testing.
Nanoencapsulated insulin preparations also show promise as
a potential oral delivery system, but this research is at an
earlier stage and needs more extensive testing in animals
before progressing to human evaluation.
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